secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2024-10-02T23:59:59+00:00
Accession:  0001682852-24-000052
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna appoints Abbas Hussain, ex-CEO of Vifor Pharma, to Board of Directors
-----------------------------------------------------------------------------

- Hussain appointed effective Oct 2, 2024; board size fixed at nine directors.
- He brings over 35 years of healthcare leadership, including former CEO of Vifor Pharma and Global President of GSK Pharmaceuticals & Vaccines.
- Hussain will serve on the Audit Committee and receive standard non-employee director compensation plus initial and pro-rata annual equity grants.
- No arrangements or relationships requiring disclosure under Item 404(a) of Regulation S-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000168285224000052/0001682852-24-000052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000168285224000052/mrna-20240928.htm
  HTML page:      https://secwatch.observer/filing/0001682852-24-000052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer